Method We studied 61 2–8 year-old children (including 7 with Down’s syndrome) attending audiology clinics with OME (n=38) and normal hearing (n=23). Children and parents were observed and questioned during their first use of the app to assess acceptability and usability. One week later, they were contacted about home use. Additionally, 18 clinicians completed questionnaires regarding use of the app in managing OME.

Results 80% of children liked the app and 90% found it easy to use. In children with Down’s Syndrome, accessibility depended on developmental age and previous app experience rather than chronological age. 89% of parents wanted their child to use the app regularly. Despite finding no significant correlation between the app’s hearing screen and audiology clinic results (p=0.381), 80% of parents felt more confident gauging and communicating their child’s hearing levels. 89% of families used the app at home and 75% felt it helped their child’s speech development.

78% of clinicians would like patients to use the app regularly, and 89% believed it would help parents support their child’s development.

Conclusions The ‘Hear Glue Ear’ app is acceptable to children, parents and clinicians. It offers an affordable and accessible means to monitor hearing at home, deliver speech and language therapy remotely, and support speech development during the ‘watchful waiting’ period of OME management.

Down syndrome medical interest group, british association of community child health and british paediatric respiratory society

G267 PREVENTING INFECTION AND MORTALITY IN DOWN SYNDROME – THE NOTTINGHAM EXPERIENCE

1,2AP Prayle, 1P Shires, 3V Baicher, 1S Smith, 1L Walton, 1E McDermott, 1E Marder. 1Family Health, Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Child Health, The University of Nottingham, Nottingham, UK; 3Emergency Department, Nottingham University Hospitals NHS Trust, Nottingham, UK; 4Immunology, Nottingham University Hospitals NHS Trust, Nottingham, UK

10.1136/archdischild-2020-rcpch.231

Background Congenital CMV [cCMV] is a leading cause of hearing loss and childhood disability. Recent research demonstrated children’s long-term outcomes could be improved with antiviral treatment offered within the first month of life. During the COVID-19 pandemic, national hearing screening guidance promoted prioritisation of face-to-face diagnostic auditory brainstem response [ABR] in infants with cCMV.

Aim To identify babies with cCMV and hearing loss within 1 month of life to ensure:

- Greater certainty of the diagnosis of cCMV.
- Early paediatric referral for identification and management of cCMV.
- Timely consideration of treatment.

Method A truly joined-up, multidisciplinary approach was taken across the region (newborn hearing screeners, audiologists, ENT surgeons, virologists, neonatologists, paediatricians, ophthalmologists). Targeted cCMV testing was undertaken by newborn hearing screeners in all babies who ‘failed’ their otocacoustic emission and automated ABR. CMV positive babies were referred urgently to paediatricians to consider management and treatment within 1 month of life. We derived data on the timing of cCMV testing in the months before and then during the pandemic.

Results Regional hospitals worked together to write the East of England CMV guidelines which were then ratified. https://www.networks.nhs.uk/nhs-networks/oeo-neonatal-odn/guidelines/current-guidelines/congenital-cmv-guideline

Following implementation in early 2019, Addenbrookes Hospital data showed that babies undergoing hearing screening during the pandemic could be prioritised according to national guidance for definitive ABR testing.

Conclusion CMV saliva swabs for babies born with hearing loss was implemented across the East of England region using a wide multidisciplinary approach. In the pandemic, this enabled prioritisation of diagnostic ABR testing in babies with cCMV and hearing impairment according to national guidance.

Purpose Children with Trisomy 21 are at increased risk of death compared to age-matched controls. We recently undertook a retrospective review of mortality in Trisomy 21 in our tertiary non-cardiac centre, and found an infective cause of death in 9/16 cases.

Methods In response to these data, we have undertaken a number of interventions at the Trust level with the goal of reducing the risk of future mortality and morbidity:

- New local guidance for preventing infection in Trisomy 21.
- Aggressively treating comorbidities such as reflux and sleep related breathing disorders.
- Protocol driven assessment of immune function including functional antibodies and meticulous immunisation.
- We recommend influenza and pneumovax II for all.
- An alert on the Trust wide computer system for patients when they present in the emergency department or on the Children’s Assessment Unit to emphasise the risk of infection in Trisomy 21.
- A review of how often and why children with Trisomy 21 present to ED.
- Increasing awareness for parents, including an alert in the Down syndrome insert for the parent held child health record (the ‘red book’).
- A standardized alert sentence on all letters to primary care from the Trisomy 21 clinic emphasising the risk of infection.
- Increasing awareness amongst Clinicians, through programmed teaching, bulletins, and alerts.